CEACAM5 and lung cancer: Clinical studies have shown that lung cancer patients with high serum levels of Cyfra21-1 and CEA in the advanced stages (III and IV) exhibit shorter survival rates and are deemed to be good candidates for adjuvant chemotherapy [37,38].